# The Bound-Free Phase Detection Immunoassay (BFPD-IA) Development, integration, and validation

Contact: Dr. Konstantinos Mitsakakis, Group Leader Immunoassays, Bioanalysis Division, Hahn-Schickard & IMTEK, University of Freiburg, Germany

Email: Konstantinos.Mitsakakis@Hahn-Schickard.de







Federal Ministry of Education and Research





### Operating principle

BFPD-IA components (indicatively for a competitive format): (a) magnetic beads (MB) coupled with capture antibody, (b) fluorescent beads (FB) coupled with competitive antigen, (c) one assay buffer, and (d) the sample.

BFPD-IA steps: (1) Addition of all reagents in one well (75 μL). (2) Single-step incubation. (3) Separation of magnetic beads. (4) Fluorescence detection in the bound-free phase.




Fig. 1: Workflow of BFPD-IA


#### Demonstration in microtiter plate (MTP)<sup>1</sup>

- Diverse biomarkers (CRP, MMP-8, MMP-9, TIMP-1)
- Diverse specimens: serum, saliva
- Concentration ranges: mg/L, ng/mL
- Sandwich and competitive format
- Single, du/triplex (fluorescence)
- Rapid (~20 min) wash-free assay



### Validation with clinical samples<sup>2</sup>

Stratification of patients with Respiratory Tract Infections (RTIs) in concentration zones (low/high cutoffs: 20/100 mg/L)






Fig. 2: CRP in clinical serum samples (N = 37)

## Integration of BFPD-IA in PCR-performing instruments<sup>3</sup>

- PCR-Disk for pathogen detection
- ImmunoDisk for biomarker detection Respiratory infections
- Same instrument for both
- Sepsis diagnosis
- Tropical diseases




Fig. 3: BFPD-IA enables PCR & Immunoassay on the same instrument

- [1] B. Johannsen, et al. Anal. Chim. Acta 2021; 1153:338280
- [2] B. Johannsen, et al. Biosensors 2023; 13:1009
- [3] B. Johannsen, et al. Stud. in Health Technol. Inform. 2020; 273:234-239
- [4] B. Johannsen, et al. Biosensors 2022; 12(6):413

#### The Sample-to-Answer (S2A) ImmunoDisk<sup>4</sup>

 Workflow: (1) Insert serum. (2) Centrifugally open stickpack & release buffer. (3) Rehydrate fluorescent beads. (4) Rehydrate magnetic beads  $\rightarrow$  incubate  $\rightarrow$  separate  $\rightarrow$  detect all in the same 'multi-purpose' chamber.




Fig. 4: Left: A sample-to-answer ImmunoDisk, with figure of the separated (centrifuged) MB in the 'multi-purpose' chamber, prior to the FB detection. Right: A functional model of the LabDisk Player, capable of processing Immuno- and PCR-Disks<sup>5</sup>.





Fig. 5: Left: A standard curve acquired with the ImmunoDisk. Right: Certified Reference Material (CRM) quantified using the ImmunoDisk.

# The mid-throughput ImmunoDisk<sup>6</sup>


- 2 half disks per run → 14 data points per run
- 27 clinical samples tested: 81.5% agreement with MTP



6: Left: Design of the mid-throughput ImmunoDisk. Middle: A commercial PCR device for which the ImmunoDisk was adapted. Right: A standard curve for measuring 27 clinical samples.

#### The future

Integration of BFPD-IA in commercially available reaction wells in non-microfluidic systems



- A robotic liquid handling platform with LAMP isothermal amplification for sepsis (BMBF project DiagnoSeps)<sup>7</sup>
- A compact, battery-operated, LAMP-compatible POC instrument for Respiratory Tract Infections in sub-Saharan Africa (EU project HOLICARE)<sup>8</sup>
- [5] M. Rombach, et al. Analyst 2020; 145:7040-7047
- [6] B. Johannsen, et al. Proceedings 2024; 97:166
- [7] https://www.hahn-schickard.de/en/projects/projects/diagnoseps
- [8] https://holicare-project.org/